Last Updated: 7.30.20

Our Clinical Development Program

For more than 140 years, Lilly has been working to discover medicines that make life better for people living with cancer. Because no two cancer patients are alike, Lilly Oncology is committed to developing novel treatment approaches. Our quest is to accelerate the pace and progress of cancer care by providing a broad portfolio of medicines that make a meaningful difference, including those designed to help people with rare and under-covered diseases.

Pipeline at a Glance

You can interact with our Pipeline at a Glance below by turning categories on or off. By default, all categories are turned off.
Reset
Clinical Phase
Phase III
Phase II
Phase I
Cancer Type
Breast Cancer
Early Development
Gastrointestinal Cancer
Genitourinary Cancer
Gynecologic Cancer
Lung Cancer
Neurologic Cancer
Sarcoma
Thyroid Cancer
Enrollment Status
Enrolling
Aurora A Kinase Inhibitor
Cancer Cell Signaling
1
Trial
BTK Inhibitor
Cancer Cell Signaling
1
Trial
CD73 Inhibitor
Immuno-Oncology
1
Trial
CDK4 & 6 Inhibitor
Cancer Cell Signaling
14
Trials
ERK1/2 Inhibitor
Cancer Cell Signaling
1
Trial
PDGFRα Antibody
Cancer Angiogenesis and Tumor Microenvironment
4
Trials
RET Inhibitor
Cancer Cell Signaling
4
Trials
Selective ER Degrader
Cancer Cell Signaling
1
Trial
Cancer Type
Trial ID
Enrolling
Clinical Phase
VEGF Receptor-2 Antagonist
Cancer Angiogenesis and Tumor Microenvironment
8
Trials
The safety and efficacy of the agents under investigation have not been established. There is no guarantee that the agents will receive regulatory approval and become commercially available for the uses being investigated.